» Articles » PMID: 29794149

NLRP3 Regulates Platelet Integrin αIIbβ3 Outside-in Signaling, Hemostasis and Arterial Thrombosis

Abstract

In addition to their hemostatic function, platelets play an important role in regulating the inflammatory response. The platelet NLRP3 inflammasome not only promotes interleukin-1β secretion, but was also found to be upregulated during platelet activation and thrombus formation However, the role of NLRP3 in platelet function and thrombus formation remains unclear. In this study, we aimed to investigate the role of NLRP3 in platelet integrin αIIbβ3 signaling transduction. Using mice, we showed that NLRP3-deficient platelets do not have significant differences in expression of the platelet-specific adhesive receptors αIIbβ3 integrin, GPIba or GPVI; however, platelets transfused into wild-type mice resulted in prolonged tail-bleeding time and delayed arterial thrombus formation, as well as exhibiting impaired spreading on immobilized fibrinogen and defective clot retraction, concomitant with decreased phosphorylation of c-Src, Syk and PLCγ2 in response to thrombin stimulation. Interestingly, addition of exogenous recombinant interleukin-1β reversed the defect in platelet spreading and clot retraction, and restored thrombin-induced phosphorylation of c-Src/Syk/PLCγ2, whereas an anti-interleukin-1β antibody blocked spreading and clot retraction mediated by wild-type platelets. Using the direct NLRP3 inhibitor, CY-09, we demonstrated significantly reduced human platelet aggregation in response to threshold concentrations of collagen and ADP, as well as impaired clot retraction in CY-09-treated human platelets, supporting a role for NLRP3 also in regulating human platelet αIIbβ3 outside-in signaling. This study identifies a novel role for NLRP3 and interleukin-1β in platelet function, and provides a new potential link between thrombosis and inflammation, suggesting that therapies targeting NLRP3 or interleukin-1β might be beneficial for treating inflammation-associated thrombosis.

Citing Articles

Prion protein fragment (106-126) activates NLRP3 inflammasome and promotes platelet-monocyte/neutrophil interactions, potentially contributing to an inflammatory state.

Verma R, Kailashiya J, Mukherjee A, Chaurasia R, Dash D Front Cell Dev Biol. 2025; 13:1534235.

PMID: 40070881 PMC: 11895701. DOI: 10.3389/fcell.2025.1534235.


Biomedical application of TiONPs can cause arterial thrombotic risks through triggering procoagulant activity, activation and aggregation of platelets.

Bian Y, Jin Q, He J, Ngo T, Bae O, Xing L Cell Biol Toxicol. 2024; 40(1):67.

PMID: 39110362 PMC: 11306309. DOI: 10.1007/s10565-024-09908-y.


NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.

Ramachandran R, Manan A, Kim J, Choi S Exp Mol Med. 2024; 56(7):1488-1500.

PMID: 38945951 PMC: 11297159. DOI: 10.1038/s12276-024-01261-8.


NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development.

Haque I, Thapa P, Burns D, Zhou J, Sharma M, Sharma R Int J Mol Sci. 2024; 25(11).

PMID: 38892264 PMC: 11172514. DOI: 10.3390/ijms25116078.


Detection of inflammasome activation in liver tissue during the donation process as potential biomarker for liver transplantation.

Mateo S, Vidal-Correoso D, Munoz-Morales A, Jover-Aguilar M, Alconchel F, de la Pena J Cell Death Discov. 2024; 10(1):266.

PMID: 38816358 PMC: 11139956. DOI: 10.1038/s41420-024-02042-y.


References
1.
Flevaris P, Stojanovic A, Gong H, Chishti A, Welch E, Du X . A molecular switch that controls cell spreading and retraction. J Cell Biol. 2007; 179(3):553-65. PMC: 2064799. DOI: 10.1083/jcb.200703185. View

2.
Swieringa F, Kuijpers M, Heemskerk J, van der Meijden P . Targeting platelet receptor function in thrombus formation: the risk of bleeding. Blood Rev. 2014; 28(1):9-21. DOI: 10.1016/j.blre.2013.12.001. View

3.
Clark E, Shattil S, Ginsberg M, Bolen J, Brugge J . Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha IIb beta 3. J Biol Chem. 1994; 269(46):28859-64. View

4.
Qiao J, Wu Y, Wu X, Liu Y, Li X, Ju W . An absence of platelet activation following thalidomide treatment in vitro or in vivo. Oncotarget. 2017; 8(22):35776-35782. PMC: 5482616. DOI: 10.18632/oncotarget.16205. View

5.
Beaulieu L, Lin E, Mick E, Koupenova M, Weinberg E, Kramer C . Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol. 2014; 34(3):552-64. PMC: 4070375. DOI: 10.1161/ATVBAHA.113.302700. View